CN116940670A8 - 一种新型嵌合受体组合物、重组载体、细胞及其应用 - Google Patents

一种新型嵌合受体组合物、重组载体、细胞及其应用 Download PDF

Info

Publication number
CN116940670A8
CN116940670A8 CN202280008263.XA CN202280008263A CN116940670A8 CN 116940670 A8 CN116940670 A8 CN 116940670A8 CN 202280008263 A CN202280008263 A CN 202280008263A CN 116940670 A8 CN116940670 A8 CN 116940670A8
Authority
CN
China
Prior art keywords
chimeric receptor
car
nkg2d
cell
novel chimeric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202280008263.XA
Other languages
English (en)
Other versions
CN116940670B (zh
CN116940670A (zh
Inventor
孙敏敏
李彦涛
王有涛
郝瑞栋
钟云鹏
易桥勇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suzhou Yimufeng Biotechnology Co ltd
Original Assignee
Suzhou Yimufeng Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suzhou Yimufeng Biotechnology Co ltd filed Critical Suzhou Yimufeng Biotechnology Co ltd
Priority to CN202410669077.1A priority Critical patent/CN118652351A/zh
Publication of CN116940670A publication Critical patent/CN116940670A/zh
Publication of CN116940670A8 publication Critical patent/CN116940670A8/zh
Application granted granted Critical
Publication of CN116940670B publication Critical patent/CN116940670B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464466—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the structure of the chimeric antigen receptor [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/11—Antigen recognition domain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/11—Antigen recognition domain
    • A61K2239/13—Antibody-based
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/17—Hinge-spacer domain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/21—Transmembrane domain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

一种新型嵌合受体组合物、重组载体、细胞及其应用。该新型嵌合受体组合物包括传统的嵌合抗原受体和包括NKG2D、DAP10和/或DAP12的全长序列或者截短片段的NKG2D嵌合受体，简称SNR武装的CAR。所述嵌合受体组合物使常规CAR-T细胞表达NKG2D胞外区及胞内信号区，扩大CAR-T抗原识别谱，解决肿瘤异质性，在增强CAR-T对表达目标靶抗原肿瘤细胞的杀伤能力的同时，实现了较低水平的因子释放，降低因子风暴发生的可能，增加CAR-T安全性。
CN202280008263.XA 2021-07-14 2022-07-12 一种新型嵌合受体组合物、重组载体、细胞及其应用 Active CN116940670B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410669077.1A CN118652351A (zh) 2021-07-14 2022-07-12 一种新型嵌合受体组合物、重组载体、细胞及其应用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202110793058.6A CN113621073A (zh) 2021-07-14 2021-07-14 一种新型嵌合受体组合物、重组载体、细胞及其应用
CN2021107930586 2021-07-14
PCT/CN2022/105029 WO2023284700A1 (zh) 2021-07-14 2022-07-12 一种新型嵌合受体组合物、重组载体、细胞及其应用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410669077.1A Division CN118652351A (zh) 2021-07-14 2022-07-12 一种新型嵌合受体组合物、重组载体、细胞及其应用

Publications (3)

Publication Number Publication Date
CN116940670A CN116940670A (zh) 2023-10-24
CN116940670A8 true CN116940670A8 (zh) 2024-01-05
CN116940670B CN116940670B (zh) 2024-07-02

Family

ID=78379685

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202110793058.6A Withdrawn CN113621073A (zh) 2021-07-14 2021-07-14 一种新型嵌合受体组合物、重组载体、细胞及其应用
CN202280008263.XA Active CN116940670B (zh) 2021-07-14 2022-07-12 一种新型嵌合受体组合物、重组载体、细胞及其应用
CN202410669077.1A Pending CN118652351A (zh) 2021-07-14 2022-07-12 一种新型嵌合受体组合物、重组载体、细胞及其应用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202110793058.6A Withdrawn CN113621073A (zh) 2021-07-14 2021-07-14 一种新型嵌合受体组合物、重组载体、细胞及其应用

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202410669077.1A Pending CN118652351A (zh) 2021-07-14 2022-07-12 一种新型嵌合受体组合物、重组载体、细胞及其应用

Country Status (6)

Country Link
US (1) US20240316105A1 (zh)
EP (1) EP4372010A1 (zh)
JP (1) JP2024525807A (zh)
KR (1) KR20240023433A (zh)
CN (3) CN113621073A (zh)
WO (1) WO2023284700A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113621073A (zh) * 2021-07-14 2021-11-09 上海易慕峰生物科技有限公司 一种新型嵌合受体组合物、重组载体、细胞及其应用
CN114106199B (zh) * 2021-11-19 2022-07-12 广州百暨基因科技有限公司 靶向adgre2的嵌合抗原受体及其应用
CN114181311B (zh) * 2021-12-20 2023-06-20 华东师范大学 一种全人源抗DLL3 scFv及其在CART细胞治疗中的应用
CN114409782B (zh) * 2021-12-29 2023-06-30 华道(上海)生物医药有限公司 一种抗IL13Ra2的纳米抗体及其应用
CN117279949B (zh) * 2022-05-27 2024-08-02 苏州易慕峰生物科技有限公司 包含cldn18.2单域抗体的嵌合抗原受体及其应用
CN117736340B (zh) * 2023-12-20 2024-07-26 青岛麦迪赛斯医疗技术有限公司 一种靶向cll-1和nkg2dl的嵌合抗原受体nk细胞的构建及应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117384929A (zh) * 2017-03-27 2024-01-12 新加坡国立大学 一种编码由细胞表达的嵌合受体的多核苷酸
CN107759701B (zh) * 2017-10-27 2021-07-02 杭州优善生物科技有限公司 嵌合抗原受体、其修饰的NK细胞、编码DNA、mRNA、表达载体、制备方法和应用
US20210024608A1 (en) * 2018-04-06 2021-01-28 H. Lee Moffitt Cancer Center And Research Institute, Inc. Nkg2d chimeric antigen receptors
CN109280087B (zh) * 2018-10-17 2020-05-15 新乡医学院 一种双靶向转换受体、编码基因、重组表达载体、抗肿瘤nk细胞及其制备方法、应用
US20200308248A1 (en) * 2019-03-26 2020-10-01 ST Phi Therapeutics Chimeric Natural Killer Cell Receptors and Method of Using Thereof
CN110698564B (zh) * 2019-10-12 2023-04-07 华夏源（上海）细胞基因工程股份有限公司 一种双靶点嵌合抗原受体及其表达载体和应用
CN110981970B (zh) * 2019-12-25 2023-03-07 华夏源（上海）细胞基因工程股份有限公司 一种靶向nkg2d配体和cd19的双靶点嵌合抗原受体及其表达载体和应用
CN111995688B (zh) * 2020-08-13 2024-01-16 金鑫 靶向cd123和nkg2d配体的双特异嵌合抗原受体及应用
CN113621073A (zh) * 2021-07-14 2021-11-09 上海易慕峰生物科技有限公司 一种新型嵌合受体组合物、重组载体、细胞及其应用

Also Published As

Publication number Publication date
JP2024525807A (ja) 2024-07-12
EP4372010A1 (en) 2024-05-22
CN116940670B (zh) 2024-07-02
CN113621073A (zh) 2021-11-09
KR20240023433A (ko) 2024-02-21
CN118652351A (zh) 2024-09-17
CN116940670A (zh) 2023-10-24
US20240316105A1 (en) 2024-09-26
WO2023284700A1 (zh) 2023-01-19

Similar Documents

Publication Publication Date Title
CN116940670A8 (zh) 一种新型嵌合受体组合物、重组载体、细胞及其应用
Schleypen et al. Renal cell carcinoma‐infiltrating natural killer cells express differential repertoires of activating and inhibitory receptors and are inhibited by specific HLA class I allotypes
EP3636761A1 (en) Antigen-binding protein recognizing mage-a4-derived peptide
WO2020014132A3 (en) Antibodies binding to ilt4
DK1734049T3 (da) Tumorassocierede peptider, der binder til MHC-molekyler
Song et al. Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression
US20200308248A1 (en) Chimeric Natural Killer Cell Receptors and Method of Using Thereof
WO2006000830A3 (en) Cells expressing a modified t cell receptor
WO2003016468A3 (en) Antagonistic anti-htnfsf13b human antibodies
Zhou et al. Dynamic constitutive and failure behavior of a two-phase tungsten composite
JP2021500882A5 (zh)
JP2020536531A5 (zh)
WO2020247371A8 (en) Anti-psgl-1 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof
Ellingford et al. Understanding the enhancement and temperature-dependency of the self-healing and electromechanical properties of dielectric elastomers containing mixed pendant polar groups
Pfirschke et al. T cell responses in early-stage melanoma patients occur frequently and are not associated with humoral response
BR9812295A (pt) Composições para o tratamento pessoal compreendendo um copolìmero adesivo
Shao et al. An anti-pressure, fatigue-resistant and rapid self-healing hydrogel based on a nano-micelle assembly
CN103484055B (zh) 一种核电机云母带用硅树脂组合物、制备方法及其用途
CN114106766A (zh) 水性聚氨酯电声胶黏剂及其制备方法
Hansen et al. ALCAM: basis sequence: mouse
Bailey et al. Comparative Sliding-wear Behavior of a Dental Amalgam and a Composite Restorative as a Function of Contact Stress.
WO2022241290A3 (en) Nkg2c+ t cells and methods of use thereof
Pourhoseingholi et al. Decreased trend of pancreatic cancer mortality in Iran
KR20240096513A (ko) 치료 세포의 제조를 위한 시스템 및 방법
Calvez et al. Associations between type of product and inhibitors in previously untreated patients (PUPs) with severe hemophilia: switches and particular products can disturb analysis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CI02 Correction of invention patent application

Correction item: Classification number

Correct: C07K 19/00(2006.01)|C12N 5/10(2006.01)|A61P 35/00(2006.01)|A61K 39/00(2006.01)

False: C12N 5/10(2006.01)

Number: 43-01

Page: The title page

Volume: 39

Correction item: Classification number

Correct: C07K 19/00(2006.01)|C12N 5/10(2006.01)|A61P 35/00(2006.01)|A61K 39/00(2006.01)

False: C12N 5/10(2006.01)

Number: 43-01

Volume: 39

CI02 Correction of invention patent application
GR01 Patent grant